Connor Clark & Lunn Investment Management Ltd. Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Connor Clark & Lunn Investment Management Ltd. reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 40.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 22,273 shares of the biopharmaceutical company’s stock after selling 15,008 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Agios Pharmaceuticals were worth $990,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quest Partners LLC grew its position in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,283 shares during the last quarter. Atria Investments Inc boosted its holdings in shares of Agios Pharmaceuticals by 47.4% in the third quarter. Atria Investments Inc now owns 10,628 shares of the biopharmaceutical company’s stock valued at $472,000 after acquiring an additional 3,418 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Agios Pharmaceuticals by 19.3% in the third quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock valued at $1,737,000 after acquiring an additional 6,320 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Agios Pharmaceuticals by 14.6% in the third quarter. Oak Ridge Investments LLC now owns 40,378 shares of the biopharmaceutical company’s stock valued at $1,794,000 after acquiring an additional 5,142 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock valued at $486,000 after acquiring an additional 4,272 shares in the last quarter.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $58.66 on Thursday. The firm has a 50 day simple moving average of $47.93 and a 200-day simple moving average of $45.04. The firm has a market cap of $3.35 billion, a PE ratio of 5.12 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 1-year low of $20.96 and a 1-year high of $62.58.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AGIO shares. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $60.00 to $56.00 in a report on Friday, September 27th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.